[Evaluation of the coagulation and fibrinolysis system in 54 patients with type 2 diabetes mellitus: correlations with lipid metabolism and blood glucose control].
Diabetic patients have increased morbidity and mortality attributable to myocardial infarction, cerebrovascular disease and peripheral vascular disease, due to a high incidence of premature atherosclerosis. Abnormalities of hemostasis have been reported in many studies on diabetes over almost thirty years, but unfortunately the results have often appeared contradictory. The hemostatic alterations could lead to increased risk of vascular disease in diabetic patients. We have studied some coagulation factors (Fibrinogen, Factor II, Factor VII) and coagulation inhibitors (Protein C, Protein S), and plasminogen in fifty-four type 2 diabetic patients. The possible relationship between coagulation factors and coagulation inhibitors and parameters for glyco-metabolic control (glycosylated hemoglobin, fructosamine) and disturbed lipid metabolism (cholesterol, triglycerides) have ben analyzed. Our results show increase of fibrinogen, correlated with the metabolic control of the disease, positive correlation between plasminogen, factor II, protein S and hypertriglycerides, decreased levels of protein C correlated neither with metabolic control of disease neither with disturbed lipid metabolism.
Moccia
F
F
Dip. Emergenza, Medicina d'Urgenza e Pronto Soccorso, Ospedale San Martino di Genova.
Colla
G
G
Castelli
F
F
Greco
G M
GM
D000368:Aged; D000369:Aged, 80 and over; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000032:analysis; D001786:Blood Glucose / Q000032:analysis*; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000378:metabolism; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D001779:Blood Coagulation Factors; D001786:Blood Glucose; D014280:Triglycerides; D002784:Cholesterol
Valutazione del sistema coagulativo e fibrinolitico in 54 pazienti con diabete mellito tipo 2; correlazioni con il metabolismo lipidico e il controllo glicometabolico.